Open AccessExecutive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China
Author(s) -
Mei Chang-Lin,
Xue Cheng,
Yu Sheng-Qiang,
Dai Bing,
Chen Jiang-Hua,
Li Ying,
Chen Li-Meng,
Liu Zhang-Suo,
Wu Yong-Gui,
Hu Zhao,
Zha Yan,
Liu Hong,
Zhuang Yong-Ze,
Zhang Chun,
Xiao Xiang-Cheng,
Wang Yue,
Li Gui-Sen,
Ma Yi-Yi,
Li Lin
Publication year - 2020
Publication title -
kidney diseases
Language(s) - English
Resource type - Journals
eISSN - 2296-9357
pISSN - 2296-9381
DOI - 10.1159/000506288
Subject(s) - guidelines
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary.